AVEO - AVEO Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.3600
+0.0900 (+3.96%)
As of 1:54PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.2700
Open2.2700
Bid2.3400 x 800
Ask2.3500 x 900
Day's Range2.2600 - 2.3650
52 Week Range1.8600 - 4.2400
Volume709,612
Avg. Volume2,468,051
Market Cap364.183M
Beta1.14
PE Ratio (TTM)N/A
EPS (TTM)-0.3170
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.88
Trade prices are not sourced from all markets
  • Business Wire4 days ago

    AVEO Announces Pricing of $5.7 Million Public Offering of Common Stock

    AVEO Pharmaceuticals, Inc. (AVEO) today announced that it has priced an underwritten public offering of 2,500,000 shares of common stock at a price to the public of $2.26 per share, the closing price as of yesterday, August 16, 2018, which would result in aggregate gross proceeds of approximately $5.7 million before underwriting discounts. All of the shares in the offering are to be sold by AVEO. AVEO has also granted the underwriter a 30-day option to purchase up to an additional 375,000 shares of common stock on the same terms and conditions.

  • Benzinga4 days ago

    The Daily Biotech Pulse: Aveo Slips On Stock Offering, FDA Greenlights Generic EpiPen, Pfenex Exec Resigns

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 16) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Eli Lilly And ...

  • ACCESSWIRE4 days ago

    Today's Research Reports on Trending Tickers: Array BioPharma and AVEO Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 17, 2018 / U.S. markets bounced back on Thursday after Walmart and Cisco reported upbeat quarterly earnings. The Dow Jones Industrial Average jumped 1.58 percent to close ...

  • Business Wire5 days ago

    AVEO Announces Proposed Offering of Common Stock

    AVEO Pharmaceuticals, Inc. (AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The net proceeds of the offering are expected to be used for working capital and general corporate purposes, including development and pre-commercial expenses incurred in connection with the ongoing Phase 3 clinical trial of tivozanib in the third-line treatment of patients with advanced renal cell carcinoma (“aRCC”) as well as the ongoing Phase 1b/2 clinical trial of tivozanib in combination with OPDIVO® (nivolumab).

  • Business Wire7 days ago

    AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China

    AVEO Oncology (AVEO) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences’ Investigational New Drug (IND) Application for a Phase Ib/III clinical trial of CAN017 (AV-203), AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate, in esophageal squamous cell cancer (ESCC). Under the terms of a March 2016 agreement, the acceptance of this IND triggers a $2 million milestone payment to AVEO from CANbridge Life Sciences. CANbridge licensed worldwide rights, excluding the United States, Canada, and Mexico, to AV-203 from AVEO and AVEO is eligible to receive up to $40 million in potential additional development and regulatory milestone payments and up to $90 million in potential commercial milestone payments, assuming the successful achievement of specified development, regulatory and commercialization objectives.

  • AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss
    Zacks13 days ago

    AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss

    AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.

  • AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates
    Zacks14 days ago

    AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Lags Revenue Estimates

    AVEO (AVEO) delivered earnings and revenue surprises of -150.00% and -67.93%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press14 days ago

    AVEO: 2Q Earnings Snapshot

    The Cambridge, Massachusetts-based company said it had profit of 6 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The results did not meet Wall Street expectations. ...

  • Business Wire14 days ago

    AVEO Reports Second Quarter 2018 Financial Results and Provides Business Update

    AVEO Oncology today reported financial results for the second quarter ended June 30, 2018 and provided a business update.

  • Business Wire20 days ago

    AVEO Oncology to Present at the Canaccord Genuity 38th Annual Growth Conference

    AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.

  • AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?
    Zacks21 days ago

    AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?

    On AVEO Pharmaceuticals' (AVEO) second-quarter 2018 conference call, investors' focus will remain on the company's progress with its drug Fotivda for the first-line treatment of RCC.

  • ACCESSWIRE28 days ago

    Stock Performance Review on AVEO Pharma and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Here's Why AVEO Pharmaceuticals Inc. Jumped Today
    Motley Fool29 days ago

    Here's Why AVEO Pharmaceuticals Inc. Jumped Today

    Investors are buying into the company's explanation for a delay in clinical trial data.

  • AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 11.8% in Session
    Zackslast month

    AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 11.8% in Session

    AVEO Pharmaceuticals (AVEO) was a big mover last session, as the company saw its shares rise more than 11% on the day amid huge volumes.

  • Business Wirelast month

    AVEO Oncology Issues Statement Regarding Revised TIVO-3 Trial Guidance

    AVEO Oncology (AVEO) today issued the following statement regarding its recently revised guidance on the timing of topline data from the TIVO-3 study, its Phase 3 trial of tivozanib as a third-line treatment for advanced renal cell carcinoma. “The Company expects to report topline results from the TIVO-3 study in the fourth quarter of 2018, approximately 6-8 weeks after the trial records 255 progression free survival (PFS) events. The one-time adjustment in the event count is the result of an administrative error that occurred from counting, as PFS events, the deaths of ten patients who had left the study without documented radiographic progression.

  • Aveo Pharmaceuticals’ Stock Plunged around 24.2% Yesterday
    Market Realistlast month

    Aveo Pharmaceuticals’ Stock Plunged around 24.2% Yesterday

    Yesterday, Aveo Pharmaceuticals (AVEO) issued an 8-K filing reporting its plan to release top-line data from its Phase 3 trial TIVO-3 in Q4 2018. In the US Phase 3 registrational study, the company is examining the vascular endothelial growth factor receptor (or VEGFR) 123 tyrosine kinase inhibitor (or TKI) Fotivda (tivozanib) for third-line advanced renal cell carcinoma (or RCC).

  • ACCESSWIRElast month

    Today's Research Reports on Stocks to Watch: AVEO Pharmaceuticals and ACADIA Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Shares of AVEO Pharmaceuticals were deep in the red on Tuesday after a SEC 8-K revealed that the company’s TIVO-3 data is now delayed until the fourth quarter. Shares of ACADIA Pharmaceuticals were in the green despite any news. AVEO Pharmaceuticals, Inc. shares closed down 24.21% on Tuesday with nearly 9.4 million shares traded.

  • GlobeNewswire2 months ago

    Research Report Identifies Six Flags Entertainment Corporation New, AVEO Pharmaceuticals, Chipotle Mexican Grill, NGL Energy Partners LP, DSW, and GoDaddy with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Six ...

  • ACCESSWIRE2 months ago

    Free Pre-Market Technical Pulse on AVEO Pharma and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 25, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. Last Friday, shares in Cambridge, Massachusetts-based AVEO Pharmaceuticals Inc. ended the session 4.35% higher at $2.40.

  • Business Wire2 months ago

    AVEO Oncology Added to the Russell 2000, Russell 3000, and Russell Microcap Indexes

    AVEO Oncology (AVEO) today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective after the U.S. market closed on Friday, June 22, 2018 as part of FTSE’s annual reconstitution. “We believe that inclusion in the widely referenced Russell U.S. Indexes reflects the significant progress we have made as a Company in the last year, including European approval of tivozanib for the treatment of adult patients with advanced kidney cancer,” said Michael Bailey, president and chief executive officer of AVEO. Annual Russell U.S. Indexes reconstitution captures the 4,000 largest US stocks as of May 11, ranking them by total market capitalization.

  • Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?
    Zacks2 months ago

    Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?

    Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

  • Why Is AVEO Pharmaceuticals (AVEO) Down 1.6% Since Its Last Earnings Report?
    Zacks2 months ago

    Why Is AVEO Pharmaceuticals (AVEO) Down 1.6% Since Its Last Earnings Report?

    AVEO Pharmaceuticals (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire3 months ago

    AVEO Oncology to Present at the Jefferies 2018 Healthcare Conference

    AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Jefferies 2018 Healthcare Conference in New York on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need.

  • ACCESSWIRE3 months ago

    Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space

    LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want a free Stock Review on AVEO, CLDX, and CERS sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Audentes Therapeutics Inc. (NASDAQ: BOLD), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Cerus Corp. (NASDAQ: CERS).

  • AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected
    Zacks3 months ago

    AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected

    AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.